ALSGD.PA SpineGuard SA EURONEXT down 8.33% on 09 Jan 2026: assess recovery
The ALSGD.PA stock slid 8.33% after hours to €0.099 on 09 Jan 2026, paced by heavier-than-average trade and weak short-term momentum. Volume reached 2,501,828 shares versus average 1,621,077, signalling elevated selling interest in EURONEXT trading in Europe. The move follows a recent pattern of sharp intraday swings and positions SpineGuard SA against a €0.0755 year low and €0.299 year high.
ALSGD.PA stock: Price action and immediate drivers
ALSGD.PA stock fell to €0.099 after hours, down €0.009 on the session. The intraday range was €0.0932 to €0.1074, and the stock opened at €0.0947. Market participants flagged thin free float and headline comparisons with peers on investing.com as short-term pressure points.
Trading volume of 2,501,828 exceeded the recent average, amplifying the drop. The 50-day average is €0.1196 and the 200-day average is €0.10824, which shows the stock now sits below the near-term trend.
Fundamentals and valuation of SpineGuard SA (ALSGD.PA)
SpineGuard SA reports EPS -0.04 and a trailing PE of -2.69, reflecting losses. Market cap stands at approximately €6,681,404.00, with 62,094,833 shares outstanding. Key ratios: P/S 1.55, P/B 1.36, and Debt/Equity 0.54.
Revenue per share is €0.08 and book value per share is €0.08, so the company trades near book on a tiny market cap. Current ratio is 1.07, and cash per share is €0.01, indicating limited liquidity headroom.
Technical setup, liquidity and volatility
Short-term indicators show limited momentum: RSI 47.00, MACD near 0.00, and ADX 13.17 indicating no clear trend. Bollinger bands are 0.08–0.14, and ATR is 0.01, which matches the stock’s low absolute price volatility but frequent percentage moves.
Liquidity remains uneven: average volume 1,621,077 versus recent session 2,501,828. Tight bid-ask spreads can widen on selling, increasing execution risk for larger orders.
ALSGD.PA stock: Meyka AI grade and forecast
Meyka AI rates ALSGD.PA with a score out of 100: 66.29 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are informational and not investment advice.
Meyka AI’s forecast model projects €0.07 monthly and €0.06 quarterly. Compared with the current price of €0.099, the monthly projection implies an -29.29% downside. Forecasts are model-based projections and not guarantees.
Risks, catalysts and sector context
Primary risks include continued negative net margins (-59.28% net margin), limited cash per share (€0.01), and stretched payables cycles (days payables 480). A weak operating cash flow per share (-€0.02) raises funding concerns for growth initiatives.
Catalysts that could stabilise ALSGD.PA stock include stronger DSG smart screw adoption, positive clinical data, or a clear funding update. Healthcare sector trends in Europe show modest strength, but small medical device names remain volatile.
Analyst view, price targets and trading strategy
Public analyst coverage is sparse; a company rating snapshot from 2025 shows a C- / Strong Sell on certain metrics. For active traders, short-term support sits near €0.0755 and resistance at €0.110–€0.120.
Reasonable near-term price targets: conservative €0.06, base €0.10, optimistic €0.18 if commercial rollouts accelerate. Position sizing should reflect high volatility and small market cap.
Final Thoughts
ALSGD.PA stock traded lower in after hours to €0.099, down 8.33% on 09 Jan 2026, with volume above the average. Fundamentals show negative EPS -0.04 and tight cash per share €0.01, while valuation metrics (P/S 1.55, P/B 1.36) leave little margin for error. Meyka AI’s model projects €0.07 monthly, implying -29.29% from today’s price, but the model is not a guarantee. We view SpineGuard as a high-risk, event-driven name where clinical news, sales traction, or a funding update would be the main recovery triggers. For traders, short-term support is €0.0755 and resistance near €0.12. As an AI-powered market analysis platform, Meyka AI highlights the need to size positions conservatively and track upcoming earnings and clinical milestones closely.
FAQs
What caused the ALSGD.PA stock drop today?
ALSGD.PA stock fell after hours due to heavier selling and weak short-term momentum. Volume rose to 2,501,828, and the stock trading below the 50-day average likely triggered stop orders.
What is the Meyka AI forecast for ALSGD.PA stock?
Meyka AI’s forecast model projects €0.07 monthly and €0.06 quarterly. The monthly projection implies -29.29% versus the current €0.099. Forecasts are model-based projections and not guarantees.
Is ALSGD.PA stock a buy after the drop?
ALSGD.PA stock presents high risk. Meyka AI issues a B / HOLD grade. Investors should wait for revenue uplift, cash improvements, or clear clinical progress before buying.
What are the key financial ratios for ALSGD.PA stock?
Key ratios include EPS -0.04, PE -2.69, P/S 1.55, P/B 1.36, and Debt/Equity 0.54. Current ratio is 1.07, indicating limited short-term liquidity.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
